Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль сартанов в лечении артериальной гипертонии: фокус на олмесартан
Роль сартанов в лечении артериальной гипертонии: фокус на олмесартан
Внимание: опечатка!
Уважаемые читатели! Обращаем ваше внимание на опечатку, допущенную в статье «Рандомизированное проспективное исследование лекарственного препарата Кудевита (коэнзима Q10) в лечении пациентов с ишемической болезнью сердца с сердечной недостаточностью II–III функционального класса» (Cons. Med. 2012; 1).
Вместо списка авторов статьи «Д.М.Аронов, Д.Г.Иоселиани, В.Б.Красницкий, Е.В.Ярных, Т.В.Ковтун» следует читать «Д.М.Аронов, Д.Г.Иоселиани, В.Б.Красницкий, Е.В.Ярных, Т.В.Шовкун».
Приносим свои искренние извинения Т.В.Шовкун и читателям.
Уважаемые читатели! Обращаем ваше внимание на опечатку, допущенную в статье «Рандомизированное проспективное исследование лекарственного препарата Кудевита (коэнзима Q10) в лечении пациентов с ишемической болезнью сердца с сердечной недостаточностью II–III функционального класса» (Cons. Med. 2012; 1).
Вместо списка авторов статьи «Д.М.Аронов, Д.Г.Иоселиани, В.Б.Красницкий, Е.В.Ярных, Т.В.Ковтун» следует читать «Д.М.Аронов, Д.Г.Иоселиани, В.Б.Красницкий, Е.В.Ярных, Т.В.Шовкун».
Приносим свои искренние извинения Т.В.Шовкун и читателям.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (IV пересмотр). 2010.
2. Ferrario CM. Angiotensin-(1–7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 2007; 25 (2): 162–76.
3. Ferrario CM, Martell N, Yunis C et al. Characterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 1998; 11 (2): 137–46.
4. Luque M, Martin P, Martell N et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens 1996; 14 (6): 799–805.
5. Munzel T, Sinning C, Post F et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40 (3): 180–96; 653–8.
6. Pahkala K, Heinonen OJ, Lagstrom H et al. Vascular endothelial function and leisure-time physical activity in adolescents. Circulation 2008; 118 (23): 2353–9.
7. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl. 2): S13–16.
8. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
9. Barrios V, Boccanelli A, Ewald S et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007; 27: 545–58.
10. Chrysant SG, Marbury TC, Robinson TD. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425–32.
11. Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006; 11: 135–41.
12. Williams PA. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension. J Hypertens 2001; 19 (Suppl. 2): 300.
13. Chrysant SG, Melino M et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
14. Kereiakes DJ, Neutel JM, Punzi HA et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007; 7: 361–72.
15. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006; 6: 103–13.
16. Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009; 7: 229–39.
17. Campbell M, Sonkodi S, Soucek M et al. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens 2001; 23: 345–55.
18. Watanabe LA, Wei M, Sun N et al. Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial. Curr Med Res Opin 2006; 22: 1955–64.
19. Fabia MJ, Abdilla N, Oltra R et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327–36.
20. Neutel JM, Smith DH, Weber MA et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6: 168–74.
21. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfl ammation. Circulation 2004; 110 (9): 1103–7.
22. Stumpe K, Agabiti-Rosei E, Zielinski T et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1 (2): 97–106.
23. Smith RD, Yokoyama H, Averill DB et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6 (5): 335–42.
24. Smith R, Yokoyama H, Averill DB et al. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. JASH 2008; 2 (3): 165–72.
25. Mediavilla JD, Fernandez-Torres C, Jaén Aguila F, Jiménez-Alonso J. Efecto de olmesartan medoxomilo sobre la rigidez arterial en pacientes con hipertensión arterial. Med Clin (Barc) 2007; 128: 726–9360.
26. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005; 16 (7): 2073–80.
27. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14 (5): 1212–22.
28. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004; 26 (Suppl. A): A28–A32.
29. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-91.
30. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419–30.
2. Ferrario CM. Angiotensin-(1–7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 2007; 25 (2): 162–76.
3. Ferrario CM, Martell N, Yunis C et al. Characterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 1998; 11 (2): 137–46.
4. Luque M, Martin P, Martell N et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens 1996; 14 (6): 799–805.
5. Munzel T, Sinning C, Post F et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40 (3): 180–96; 653–8.
6. Pahkala K, Heinonen OJ, Lagstrom H et al. Vascular endothelial function and leisure-time physical activity in adolescents. Circulation 2008; 118 (23): 2353–9.
7. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl. 2): S13–16.
8. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
9. Barrios V, Boccanelli A, Ewald S et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007; 27: 545–58.
10. Chrysant SG, Marbury TC, Robinson TD. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425–32.
11. Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006; 11: 135–41.
12. Williams PA. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension. J Hypertens 2001; 19 (Suppl. 2): 300.
13. Chrysant SG, Melino M et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
14. Kereiakes DJ, Neutel JM, Punzi HA et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007; 7: 361–72.
15. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006; 6: 103–13.
16. Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009; 7: 229–39.
17. Campbell M, Sonkodi S, Soucek M et al. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens 2001; 23: 345–55.
18. Watanabe LA, Wei M, Sun N et al. Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial. Curr Med Res Opin 2006; 22: 1955–64.
19. Fabia MJ, Abdilla N, Oltra R et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327–36.
20. Neutel JM, Smith DH, Weber MA et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6: 168–74.
21. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfl ammation. Circulation 2004; 110 (9): 1103–7.
22. Stumpe K, Agabiti-Rosei E, Zielinski T et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1 (2): 97–106.
23. Smith RD, Yokoyama H, Averill DB et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6 (5): 335–42.
24. Smith R, Yokoyama H, Averill DB et al. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. JASH 2008; 2 (3): 165–72.
25. Mediavilla JD, Fernandez-Torres C, Jaén Aguila F, Jiménez-Alonso J. Efecto de olmesartan medoxomilo sobre la rigidez arterial en pacientes con hipertensión arterial. Med Clin (Barc) 2007; 128: 726–9360.
26. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005; 16 (7): 2073–80.
27. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14 (5): 1212–22.
28. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004; 26 (Suppl. A): A28–A32.
29. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-91.
30. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419–30.
Авторы
Г.А.Барышникова, С.А.Чорбинская, И.И.Степанова
Кафедра семейной медицины ФГБУ Учебно-научный медицинский центр УД Президента РФ, Москва
Кафедра семейной медицины ФГБУ Учебно-научный медицинский центр УД Президента РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.